Phase II trial of alternate schedule of chemotherapy as front-line treatment in metastatic non-small cell lung cancer (NSCLC): A single-centre experience

被引：0
|
作者：
Lopez Castro, R. [1 ]
Martin, G. [1 ]
Seijas, R. [1 ]
Bellido, L. [1 ]
del Barco, E. [1 ]
Garcia, R. [1 ]
Martin, T. [1 ]
Castro, E. [1 ]
Leno, R. [1 ]
Cruz, J. [1 ]
机构：
[1] Univ Hosp Salamanca, Salamanca, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19120
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II randomized trial of single-agent pemetrexed or sequentially administered pemetrexed/gemcitabine as front-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in elderly patients or patients ineligible for platinum-based chemotherapy
    Gridelli, C
    Reck, M
    Gregorc, V
    Migliorino, M
    Favaretto, A
    Schmittel, A
    Caffo, O
    Blatter, J
    Munoz, M
    Crucitta, E
    Rossi, A
    Koschel, G
    LUNG CANCER, 2005, 49 : S245 - S245
  • [22] Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial
    Stathopoulos, GP
    Dimitroulis, J
    Antoniou, D
    Katis, C
    Tsavdaridis, D
    Armenaki, O
    Marosis, C
    Michalopoulou, P
    Grigoratou, T
    Stathopoulos, J
    BRITISH JOURNAL OF CANCER, 2005, 93 (10) : 1106 - 1111
  • [23] The Cost and the Benefit: Front-Line Immunotherapy for Non-Small Cell Lung Cancer
    Bestvina, C. M.
    Vokes, E. E.
    Hoffman, P. C.
    Patel, J. D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1552 - S1552
  • [24] Phase II trial of gemcitabine and cisplatin as first-line treatment of advanced non-small cell lung cancer (NSCLC).
    Lee, NS
    Byun, JH
    Bae, SB
    Kim, CK
    Lee, KT
    Park, SK
    Park, KK
    Won, JH
    Hong, DS
    Park, HS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 701S - 701S
  • [25] Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?
    Goldberg, Sarah B.
    Herbst, Roy S.
    CANCER, 2018, 124 (24) : 4592 - 4596
  • [26] Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial
    West, H. L.
    Wakelee, H. A.
    Perry, M. C.
    Belt, R. J.
    Chen, R.
    Obasaju, C.
    ANNALS OF ONCOLOGY, 2009, 20 (05) : 850 - 856
  • [27] Longitudinal evaluation of EGFR mutation in plasma for non-small cell lung cancer patients with front-line chemotherapy
    Hua, B.
    Zhao, J.
    Wang, S. H.
    Yang, L.
    Duan, J. C.
    Wu, M. N.
    Wang, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Ardizzoni, A
    Tiseo, M
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 104 - 107
  • [29] Is Lipoplatinum Monotherapy an Active Alternative in Second Line Treatment of Metastatic Non-Small Cell Lung Cancer? A Phase II Trial
    Ravaioli, Alberto
    Fantini, Manuela
    Drudi, Fabrizio
    Papi, Maximilian
    Pasquini, Enzo
    Marangolo, Maurizio
    Zoli, Wainer
    Panzini, Ilaria
    Rudnas, Britt
    Nicoletti, Stefania V. L.
    Possenti, Cinzia
    Tamburini, Emiliano
    Gianni, Lorenzo
    Imola, Manuela
    PLATINUM AND OTHER HEAVY METAL COMPOUNDS IN CANCER CHEMOTHERAPY: MOLECULAR MECHANISMS AND CLINICAL APPLICATIONS, 2009, : 243 - 249
  • [30] First-line treatment of metastatic non-small cell lung cancer (NSCLC): A randomized, double-blind, phase 2 trial of denosumab in combination with chemotherapy
    de Boer, R.
    Pedrazzoli, P.
    Biesma, B.
    Natale, R.
    Lee, C. K.
    Zhu, L.
    Glennane, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E130 - E130
12345